Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec;35(6):332-337.
doi: 10.1159/000504148. Epub 2019 Nov 7.

The Gut Microbiome in Inflammatory Bowel Diseases: Diagnostic and Therapeutic Implications

Konrad Aden  1 , Wolfgang Reindl  2
Affiliations
Review

The Gut Microbiome in Inflammatory Bowel Diseases: Diagnostic and Therapeutic Implications

Konrad Aden et al. Visc Med. 2019 Dec.

Abstract

The incidence of chronic inflammatory bowel diseases (IBD) is rising worldwide, and the interaction between the mucosal immune system and the intestinal microbiota is crucial for the understanding of these diseases. Due to new technologies, the data published on the intestinal microbiota has increased rapidly in the recent years. While many findings are descriptive, reporting associations between disease and microbial populations, recent advancement in technology made it possible to ask and answer more functional questions and to elucidate complex interactions between the intestinal microbiota and the mucosal immune system. In addition, first trials influenced the intestinal microbiota with the intention to treat IBD. This review summarizes aspects of the physiological function as well as the inflammation-induced changes of the gut microbiota and the association between the gut microbiota and pathogenesis in IBD. In addition, diagnostic and therapeutic options for treating IBD are reviewed.

Keywords: Dysbiosis; Fecal microbial transfer; Inflammatory bowel disease; Microbiota.

PubMed Disclaimer

Conflict of interest statement

K.A. received speaker fees from Janssen. W.R. received speaker fees from Abbvie, Janssen, Falk, and Takeda.

References

    1. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. International IBD Genetics Consortium (IIBDGC) Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012 Nov;491((7422)):119–24. - PMC - PubMed
    1. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol. 2006 Oct;12((38)):6102–8. - PMC - PubMed
    1. Cosnes J, Rousseau CG, Seksik P, Cortot A. Epidemiology and Natural History of Inflammatory Bowel Diseases. Gastroenterology Elsevier Inc. 2011 May;140((6)):1785.e4–1794.e4. - PubMed
    1. Ko Y, Butcher R, Leong RW. Epidemiological studies of migration and environmental risk factors in the inflammatory bowel diseases. World J Gastroenterol. 2014 Feb;20((5)):1238–47. - PMC - PubMed
    1. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018 Dec;390((10114)):2769–78. - PubMed